RecruitingNCT06566898

Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients

Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients: a Genomic Epidemiology Study


Sponsor

Shanghai General Hospital, China

Enrollment

800 participants

Start Date

Aug 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Monitoring of antimicrobial resistance (AMR) based on metagenomics analyses in pneumonia patients is critical for optimizing clinical diagnosis and treatment and improving clinical prognosis. This study is designed to ask the following key questions: 1. What is the microbiome maps of patients with severe pneumonia and mild pneumonia ? 2. How many pathogen resistance genes are carrying in severe pneumonia and mild pneumonia ? 3. What is the genetic diversity of key pathogens detected in severe pneumonia and mild pneumonia during 2019-2025?


Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with antimicrobial resistance, microbiome, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Mei Kang

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06566898


Related Trials